Mood stabilizers such as lithium and valproate, both commonly used in the treatment of bipolar disorder, modulate circadian rhythms via inhibition of glycogen-synthase-kinase-3-beta (GSK3Beta), which phosphorylates the cycle length determining PER clock gene products. The gene discussed is PER1; the disease is bipolar disorder.